Skip to Main Content


Schizophrenia is a psychiatric illness representing a heterogeneous syndrome of disorganized and bizarre thoughts, delusions, hallucinations, diminished emotional experience, and impaired psychosocial function. The etiology of schizophrenia is unknown, but genetics and alteration of neurotransmitters (eg, dopamine) have a significant role in the development of schizophrenia.


Positive, negative, and cognitive symptoms are the different types of symptoms associated with schizophrenia. Positive symptoms are an excess of normal functions or are added to normal functions. Delusions, defined as false, fixed beliefs and hallucinations, defined as real perception of senses in the absence of external stimuli, are examples of positive symptoms. Hallucinations may affect all five senses and are primarily categorized as visual, auditory, olfactory, tactile, and gustatory, depending on the sensation alteration. Other positive symptoms also include disorganized speech, tangentiality, disorganized behavior, and catatonic behavior. Negative symptoms are characterized by diminished emotional expression or loss of normal functions. Examples of negative symptoms include alogia, avolition, and anhedonia. Negative symptoms are difficult to assess compared to positive symptoms because they are also associated with other psychiatric disorders. Examples of cognitive symptoms are impaired attention or memory. Additionally, individuals with schizophrenia may present with social and occupational dysfunction. For example, patients may have difficulty with self-care, maintaining employment, or maintaining relationships. A common misconception is that schizophrenia means split personalities or having multiple personalities. Schizophrenia is an illness associated with various types of symptoms and is not a split personality disorder.


No objective measures exist to confirm the diagnosis of schizophrenia. Schizophrenia is diagnosed by evaluating the patient and the patient’s symptoms. The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) is a diagnostic reference that provides criteria for schizophrenia diagnosis. Characteristic symptoms, social and occupational dysfunction, duration, and the ruling out of other disorders are key components of the DSM-5 criteria for schizophrenia.


The goal of treatment is to decrease symptoms, improve quality of life, improve patient functioning, and minimizes medication side effects. Treatment options for schizophrenia include nonpharmacologic therapy and pharmacologic therapy, and both are beneficial for the treatment of schizophrenia. Nonpharmacologic therapy includes psychosocial support groups and programs that focus on enhancing patient functioning in conjunction with pharmacologic therapy. Antipsychotics are the mainstay of treatment for schizophrenia. There are two classes of antipsychotics: first-generation antipsychotics (FGAs) and atypical or second-generation antipsychotics (SGAs), also known as typical and atypical antipsychotics, respectively (Table 56-1). Both antipsychotic classes are effective for improving positive symptoms; however, SGAs are more likely to control negative symptoms when compared to FGAs. Additionally, antipsychotics are available as long-acting injectables (Table 56-2).

TABLE 56-1Antipsychotics and Dosage Ranges

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.